BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sebastian S, Neilaj S. Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment? Therap Adv Gastroenterol 2019;12:1756284818817293. [PMID: 30643542 DOI: 10.1177/1756284818817293] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Beaugerie L, Rahier JF, Kirchgesner J. Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020; 18: 1324-1335. e2. [PMID: 32059920 DOI: 10.1016/j.cgh.2020.02.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
2 Solitano V, D'Amico F, Correale C, Peyrin-Biroulet L, Danese S. Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases. Br Med Bull 2020;136:107-17. [PMID: 33200781 DOI: 10.1093/bmb/ldaa033] [Reference Citation Analysis]
3 Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Front Med 2022;9:897936. [DOI: 10.3389/fmed.2022.897936] [Reference Citation Analysis]
4 Ly NTM, Ma N, Ueda-Hayakawa I, Nguyen CTH, Anada R, Okamoto H, Fujimoto M. Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1γ antibodies. J Dermatol Sci 2021;104:177-84. [PMID: 34772582 DOI: 10.1016/j.jdermsci.2021.10.003] [Reference Citation Analysis]
5 Raja TW, Veeramuthu D, Savarimuthu I, Al-Dhabi NA. Current Trends in the Treatment of Systemic Lupus Erythematosus. Curr Pharm Des 2020;26:2602-9. [PMID: 32066358 DOI: 10.2174/1381612826666200211122633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 Dahmus J, Rosario M, Clarke K. Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy. Clin Exp Gastroenterol 2020;13:339-50. [PMID: 32982364 DOI: 10.2147/CEG.S237646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Queiroz NSF, Graciolli CB, Sobrado CW. Exposure to Tofacitinib Not Related to Recurrence of Anal Premalignant Lesion: A Case Report. Inflamm Bowel Dis 2020;26:e155-6. [PMID: 32676668 DOI: 10.1093/ibd/izaa194] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Fiorillo C, Schena CA, Quero G, Laterza V, Pugliese D, Privitera G, Rosa F, Schepis T, Salvatore L, Di Stefano B, Larosa L, Minordi LM, Natale L, Tortora G, Armuzzi A, Alfieri S. Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis. Cancers (Basel) 2021;13:574. [PMID: 33540674 DOI: 10.3390/cancers13030574] [Reference Citation Analysis]
9 Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T; HAYABUSA Study Group. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 2021;6:429-37. [PMID: 33887262 DOI: 10.1016/S2468-1253(21)00062-5] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Minnis-lyons SE, Aiken Z, Chow S, Din S. Managing IBD in patients with previous cancers. Frontline Gastroenterol 2022;13:e44-50. [DOI: 10.1136/flgastro-2022-102187] [Reference Citation Analysis]